Detalles de la búsqueda
1.
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis.
Am J Gastroenterol
; 116(Suppl 1): S9-S10, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37461957
2.
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.
Ann Rheum Dis
; 73(1): 86-94, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23962455
3.
Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial.
Arthritis Care Res (Hoboken)
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38529674
4.
Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome.
Kidney Int Rep
; 3(1): 115-121, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29340321
5.
Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
J Rheumatol
; 45(8): 1085-1092, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29657147
6.
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study.
Arthritis Care Res (Hoboken)
; 65(5): 718-28, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23097311
7.
Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
J Rheumatol
; 39(8): 1546-54, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22798265
Resultados
1 -
7
de 7
1
Próxima >
>>